BioCentury
ARTICLE | Product Development

Trials, in-hospital treatments and guidances hit snags in the wake of COVID-19

March 19, 2020 11:37 PM UTC

As vaccine and therapeutic companies ramp up clinical trials for COVID-19, other biotechs are halting trials to protect patients and to preserve hospital resources. The ripple effects of the pandemic are also beginning to play out among patients receiving in-hospital treatments and companies reporting financial expectations.

Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) said Thursday it has paused new patient enrollment in two Phase III, multicenter trials of vonoprazan out of “an abundance of caution relating to the global efforts to combat the COVID-19 pandemic.”...